The 'G2 Solutions' project, initiated by LIFE Cooperative, was officially awarded a grant by PharmaNL in August under their Shared Development Infrastructure program. This is the second grant we have received from PharmaNL this year, following the February 2024 award for the LIFE Academy under the Human Capital Growth program.
In collaboration with our partners Pivot Park Screening Centre, UMCG, and GenomeScan, this project will focus on developing new technology for improved disease diagnostics and advanced stem cell models to discover new drugs. We aim to make this technology available to academic and commercial partners, thereby collectively enhancing the availability of medicines in the Netherlands.
Peter Ketelaar, Director of LIFE Cooperative: "We are incredibly pleased and grateful for PharmaNL's grant. This recognition underscores the added value and importance of our regional ecosystem in strengthening the Dutch pharmaceutical sector. Through the 'G2 Solutions' project, we are taking a significant step forward in the development of innovative technologies and the acceleration of drug development. The shared use of advanced infrastructure allows us to work faster and more cost-effectively, ultimately contributing to better healthcare for everyone."
PharmaNL is an initiative by and for the Dutch pharmaceutical sector, supported by a national public-private consortium comprising Leiden University Medical Center/Leiden University, Campus Groningen, and Pivot Park Oss.
The PharmaNL Shared Development Infrastructure program focuses on strengthening the Dutch pharmaceutical value chain by expanding shared R&D infrastructure in pharmaceutical hubs. ZonMw executes the PharmaNL program on behalf of the Ministry of Health, Welfare, and Sport (VWS).
The development of this project has been made possible with the support of the Municipality of Groningen and the Municipality of Assen, the Provinces of Groningen, Drenthe, and Fryslân.
Source text: LIFE Cooperative
Source image: PharmaNL
MimeCure heeft een investering van 3 miljoen euro binnengehaald voor de ontwikkeling van een regeneratief geneesmiddel voor de behandeling van chronische longziekten, zoals longfibrose. Dankzij deze financiering kan MimeCure de afronding van de preklinische fase versnellen en beginnen met de voorbereidingen voor klinische proeven, die volgens planning eind 2027 van start zullen gaan. De investeringsronde wordt geleid door Addington Investment Group en ondersteund door mede-investeerder Apsara Investments.
Turning plans into results: that is the central focus of the fifth LIFE Science Conference, taking place on Tuesday, 22 September 2026 at Forum Groningen. The LIFE Cooperative will bring together professionals, entrepreneurs, researchers and policymakers from the life sciences and health sector around one key question: how do we translate vision into concrete impact? The keynote speaker will be Peter Wennink, former CEO of ASML and one of the most influential leaders in the Dutch technology sector. In 2025, he presented his advisory report ‘The Road to Future Prosperity’, in which he advocates targeted investments in innovation to strengthen the Netherlands’ long-term earning capacity.
In the North, and in Groningen in particular, there are dozens of companies working on innovations in the fields of life sciences and health. There are many hidden gems among them, says Ronald Hesse, director of the LIFE Cooperative partnership. “Millions of patients worldwide have already benefited from innovations developed here in Groningen,” he says.
